



VRL/SEC/EXCHANGE

21.11.2018

BSE Limited
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai
Script Code: 526953

Sub.: Clarification on Spurt in Price

Dear Sir/ Madam,

This is with reference to your email dated 21.11.2018 regarding increase in price of Venus Remedies Limited.

In this regard we wish to inform you that Company has issued an announcement on 15.11.2018 regarding "Phase-3 Clinical Trial for its flagship product ELORES, presented at IDWeek 2018".

We further wish to inform you that company has already disclosed the said information to its investors through both the stock exchanges namely BSE Limited and National Stock Exchange of India Ltd (NSE).

We are once again attaching herewith a copy of announcement thereof.

Thanking you.

for VENUS REMEDIES LIMITED

Company Secretary

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I, Panchkula (Hry.) 134113, India

Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India



VRL/SEC/EXCHANGE

15.11.2018

National Stock Exchange of India Ltd.
5th Floor, Exchange Plaza
Bandra (E),
Mumbai- 400 051
Script Code: VENUSREM

Dept. of Corporate Services
The Stock Exchange, Mumbai
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai
Script Code: 526953

Sub: Announcement

Dear Sir/Madam,

Please find enclosed herewith an announcement.

Thanking you.

Yours faithfully,
for VENUS REMEDIES LIMITED


(Company Secretary)



VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I, Panchkula (Hry.) 134113, India

Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566

Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India



Company announces positive Top-Line results in Phase-3 Clinical Trial for its flagship product ELORES, presented at IDWeek 2018

- *The results of plea Clinical Trial for its flagship product ELORES were presented at IDWeek2018 in San Francisco.*
- *Four abstracts were accepted for poster presentations covering data from the plea clinical trial, as well as in vitro data from an AMR surveillance study.*
- *Venus is the first Indian company to conduct a Phase-3 study of this design in the antibiotics segment.*

Venus Remedies Limited, a leading research-based global pharmaceutical company announces positive Top-Line results in the Phase-3 Clinical Trials for its flagship product ELORES. The results were presented at IDWeek 2018 in San Francisco. IDWeek is an annual scientific meeting of the Infectious Diseases Society of America (IDSA).

Company's four abstracts were accepted for poster presentations at the IDWeek 2018. These posters covered the efficacy results from the plea clinical trial, as well as supportive *in vitro* efficacy data from an AMR Surveillance study.

Plea Clinical trial is a multi-center, randomized, double-blind Phase 3 trial designed to evaluate the safety and efficacy of ELORES (Ceftriaxone + Sulbactam + EDTA) versus Meropenem for the treatment of complicated Urinary Tract Infections (cUTI) and Acute Pyelonephritis (AP). The results of the plea Clinical Trial include analysis of the primary outcomes which were defined as per the FDA & EMA guidance.

Saransh Chaudhary, CEO, Venus Medicine Research Centre said "plea trial is India's first Phase-3 clinical trial of such design in the anti-infective space and we are proud to be the first Indian company to have conducted this study & present the results at the world's largest infectious diseases event, IDWeek 2018. We believe that this will further nourish Indian research ecosystem and help in putting Indian innovations on the global research landscape."

Elores is a novel, patented critical care antibiotic combination targeting unmet medical needs in Antimicrobial Resistance (AMR) space. The global demand for antibiotics has grown significantly over the past two decades. The global antibiotics market was valued at about USD 40.86 billion in 2017, which is estimated to register a CAGR of 4.7%, over the period, 2018 to 2023. After successful representation at ID Week, October 2018 at San Francisco, Elores was launched in three important Latin American markets i.e. Colombia, Dominican Republic, Guatemala and is scheduled to be launched in Saudi Arabia on the 23rd of this month. These international launches will bring in significant revenue over the next 3-5 years and help the Company in strengthening its position in the Middle-Eastern and Latin American

markets. Elores is now available in 7 countries, with scheduled launches in another 4 territories over the next year. Elores is under registration in many parts of world.

About Venus Remedies Limited

Venus Remedies, headquartered in Panchkula, Haryana (India), is among the leading fixed-dosage injectable manufacturers in the world. The company has three manufacturing units, located in Panchkula (India), Baddi (India) and Werne (Germany), and 11 overseas marketing offices including the US and Colombia.

The manufacturing units are certified with 20+ national and International Accreditations. Venus is one of the very few R&D-driven companies in the world working on Antimicrobial Resistance, focusing on novel solutions to tackle the growing menace of superbugs. The Company's R&D center is approved by Department of Scientific and Industrial Research, Government of India (DSIR) and is located in Baddi.

Venus has won over 100 patents for its innovative research products worldwide. The company has an international presence in 60+ countries, covering over 75 products.
